An analysis of implementing pharmaceutical cost-containment measures in Egypt: lessons from international experiences

Purpose The main goal of this paper is to analyze the implementation of pharmaceuticals cost-containment measures in Egypt. Design/methodology/approach This paper adopts descriptive and analytical techniques to assess the extent of implementing pharmaceutical cost-containment measures in Egypt. A comparative approach was used to analyze and draw lessons from the French and Turkish experiences in implementing these measures. Findings The study reveals that applying pharmaceutical cost-containment policies is considered one of the top priorities of the Egyptian health authorities over the next few years. The analysis of international experiences revealed that implementing traditional cost-containment policies should not be considered as the only way to curb increasing drug spending and facing the increase in pharmaceutical prices. Instead, adopting more advanced cost-containment policies, such as improving the use of economic evaluation, using cost-effectiveness analysis and implementing HTA is highly recommended. Research limitations/implications Due to data limitations regarding the current system of coverage and reimbursement in Egypt, the assessment of the impact of pharmaceutical cost-containment policies on reimbursement and procurement systems was not addressed in this study. More studies are required to analyze these issues in light of the implementation of the new Universal Health Insurance system and its implications for the pharmaceutical market. Originality/value Although there are many studies that have analyzed pharmaceutical pricing policies in Egypt during the last few decades, to the best of the authors' knowledge, there are almost no studies that specifically try to review the implementation of pharmaceutical cost-containment policies in Egypt in detail. In this regard, the aim of this study is to analyze the implementing of pharmaceutical cost-containment policies in Egypt.